HP Ingredients Relaunches ParActin Website to Address Formulator Substantiation Questions

HP Ingredients has relaunched ParActin.com, the website supporting its branded Andrographis paniculata extract, restructuring how the company presents clinical and mechanistic evidence to product developers evaluating the ingredient.¹

The update reflects a broader pattern among ingredient suppliers, which is that as formulators face growing pressure to substantiate finished-product claims, the way clinical evidence is packaged and made accessible has become as relevant to purchasing decisions as the underlying research itself.

"Science content anchors strong-quality ingredient websites," noted Annie Eng, HP Ingredients’ founder and CEO. "Our experts translated the clinical research into easier-to-understand yet still compelling content formats, making our science more accessible to marketers, formulators and C-suite executives."

What Questions Is the New ParActin Website Designed to Answer?

According to the company, the site was structured around 6 questions product developers commonly raise during ingredient evaluation: how the ingredient works; what clinical outcomes have been demonstrated; which applications it best suits; how it compares to alternative ingredients; which version to use in specific formulations; and what supporting resources are available.¹

New features include simplified visual explanations of the ingredient's proposed mechanisms of action, a mechanism-to-benefit mapping tool intended to connect specific biological pathways to clinical outcomes, and "research cards" designed to summarize clinical findings in a more scannable format.¹ The site also adds new clinical benefit pages covering 3 categories not previously featured: pain relief, antioxidant activity, and brain health.¹

What Does the Underlying Research on Andrographis paniculata Actually Show?

Andrographis paniculata is a plant long used in traditional Asian medicine, and andrographolide, its primary bioactive diterpenoid lactone, has been the subject of a substantial and growing body of preclinical and clinical research.

A recent pharmacological review² describes andrographolide as acting on several interconnected inflammatory signaling pathways, including nuclear factor kappa B, and notes clinical evidence supporting its use in areas such as osteoarthritis and upper respiratory tract infections, alongside a considerably larger base of preclinical and mechanistic data across other potential applications.

That distinction, between mechanistic plausibility and confirmed clinical outcomes in specific applications, is relevant context for formulators evaluating any Andrographis-based ingredient, branded or otherwise, since mechanism-level research does not automatically establish efficacy for every downstream benefit claim.

How Should Formulators Evaluate a Branded Extract Against Generic Alternatives?

HP Ingredients has positioned ParActin, along with related Andrographis-based ingredients in its portfolio, as differentiated from generic Andrographis extracts and commodity botanical ingredients.¹

Eng described the update as reflecting "the growing sophistication of ingredient science and formulation technology" across the category.¹ For manufacturers, the more useful evaluation criteria remain constant regardless of how a supplier packages its content—whether specific finished-product claims are backed by human clinical trials using the exact ingredient and dose in question, rather than by mechanism-level or generic-extract research that may not transfer directly to a branded, standardized version.

References

1. HP Ingredients. HP Ingredients announces ParActin website refresh. July 2026. Accessed July 15, 2026. Press release provided via email.

2. Li X, Yuan W, Wu J, Zhen J, Sun Q, Yu M. Andrographolide, a natural anti-inflammatory agent: an update. Front Pharmacol. 2022;13:920435. doi:10.3389/fphar.2022.920435